Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 113 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Topical corticosteroid Clear all
Withdrawn Not applicable Interventional

Preoperative Corticosteroid Epidural Injection and Lumbar Decompression Surgery Outcomes

NCT03543033
View directory record Official record
Conditions
Lumbar Radiculopathy
Interventions
Corticosteroid injection
Drug
Lead sponsor
Lahey Clinic
Other
Eligibility
30 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Burlington, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery

NCT05023304
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical prednisolone acetate
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2025 · Synced Oct 21, 2026, 5:51 PM EDT
Recruiting Phase 2 Interventional

Dupilumab Versus Topical Corticosteroid Effectiveness - Comparison in the Treatment of Stenotic EoE

NCT06705387
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
Dupilumab, Fluticasone
Biological · Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 25 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The RESTORE Study, A Randomized, Controlled, Masked (Reading Center) Prospective Study

NCT04396990
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 21, 2026, 5:51 PM EDT
Withdrawn Phase 4 Interventional

Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis

NCT03626376
View directory record Official record
Conditions
Herpes Simplex Virus Keratitis
Interventions
oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily, oral acyclovir 400 mg BID OR valacyclovir 500 mg qdaily + topical corticosteroid eye drops
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 14, 2022 · Synced Oct 21, 2026, 5:51 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03568318
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Upadacitinib, Topical corticosteroids (TCS)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 75 Years
Enrollment
1,533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
59
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 21, 2026, 5:51 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

NCT03948334
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Litchfield Park, Arizona • Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional

DEXTENZA for the Treatment of Postoperative Pain and Inflammation Following Vitreo-retinal Surgery

NCT04462523
View directory record Official record
Conditions
Vitreo-Retinal Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Patrick R. Oellers, MD
Network
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Liverpool, New York
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 21, 2026, 5:51 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

DEXTENZA Compared to Topical Prednisolone in Patients Undergoing Bilateral LASIK Surgery

NCT04281862
View directory record Official record
Conditions
Refractive Surgery
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Topical Prednisolone
Drug
Lead sponsor
Vance Thompson Vision
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
West Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 21, 2026, 5:51 PM EDT
Terminated Not applicable Interventional Results available

Hydrogel Patch for the Treatment of Eczema

NCT00924508
View directory record Official record
Conditions
Eczema
Interventions
hydrogel patch, Triamcinolone (TAC) 0.1% cream
Device · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 31, 2014 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis

NCT02340234
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab, Placebo, TCS Cream
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
16
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2017 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05724199
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

NCT02349061
View directory record Official record
Conditions
Lupus Erythematosus, Systemic
Interventions
Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2020 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 2 Interventional Results available

Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis

NCT05018806
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, Rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
9
States / cities
Northridge, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 5:51 PM EDT
Recruiting Not applicable Interventional

Vibratory Anesthesia on Pain Following Corticosteroid Injections

NCT07553273
View directory record Official record
Conditions
Bilateral Arthritis of Wrist, Tendinopathy, Arthropathy, Compression Neuropathy, Bilateral Arthritis of Hands
Interventions
Digivibe Device
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

Xylitol for Chronic Sinusitis

NCT03229551
View directory record Official record
Conditions
Chronic Rhinosinusitis, Rhinosinusitis, Sinusitis, Drain Sinus, Endoscopic Sinus Surgery, Biofilms, Bacterial Overgrowth
Interventions
Xylitol, Saline
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 21, 2026, 5:51 PM EDT
Terminated Phase 4 Interventional Results available

Open Label Study of Acthar SQ Gel Injection in Patients With Active Anterior Uveitis

NCT02769702
View directory record Official record
Conditions
Uveitis
Interventions
Acthar
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 1, 2018 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).

NCT03526861
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebos
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 17 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
29
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Fountain Valley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 21, 2026, 5:51 PM EDT
Terminated Phase 4 Interventional Results available

A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal

NCT02317276
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Triamcinolone 0.1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional

ASSIST-VLA: Assessment of Symptom-Specific Improvement in Diagnosed Vaginal Atrophy Following Laser Therapy

NCT07346287
View directory record Official record
Conditions
Vaginal Atrophy, Atrophic Vaginitis, Genitourinary Syndrome of Menopause (GSM)
Interventions
7-940
Device
Lead sponsor
Stratpharma AG
Industry
Eligibility
18 Years and older · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Laguna Hills, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 21, 2026, 5:51 PM EDT
Completed Phase 4 Interventional Results available

Effect of Intraoperative Dexamethasone on Post-op Dry Eye

NCT04184999
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
dexamethasone intraocular suspension, 9%, Prednisolone Acetate 1% Oph Susp
Drug
Lead sponsor
SR Cornea Consultants
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Sycamore, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 21, 2026, 5:51 PM EDT